<p>Disease pathology among mock (top two panels) and vaccinated (bottom two panels) animals challenged with either HSV-1 (McKrae) or HSV-2 (G) 5 days post challenge. HSV-1(McKrae) and HSV-2(G) infected mice exhibited similar disease progression and pathology in the mock groups (top two panels). Vaccinated mice (bottom two panels) did not exhibit any clinical disease over the observation period post challenge. Mild disease symptoms included ruffled fur, hunching posture, inflammation and redness of vagina (top right). More serious manifestations included purulent vaginal discharge (top left).</p
<p>Groups of mice (n = 10) were infected by the intravaginal route with a single dose (ranging from ...
<p>The percentage (A) and degree (B) of morbidity of Balb/c mice immunized with pE1D2, pE2D2 and con...
WT and Usp12-/- mice were infected with HSV-1 virus (1 × 107 PFU per mouse). (A) Survival rate of WT...
<p>Mice were treated with 2 mg medoxyprogesterone 7 and 3 days prior to vaginal HSV-2 challenge. On ...
<p>(A) Pre challenge percent change in weight in mock vs vaccinated animals. Percentages normalized ...
<p>Mice were treated with 2 mg medoxyprogesterone 7 and 3 days prior to vaginal HSV-2 challenge. On ...
<p>Mice were immunized twice, three weeks apart, with MVA vectors and challenged three weeks later w...
<p>(<b>A</b>) Design of mouse vaccine-challenge experiment. Mice were immunized in their right, rear...
<p>Ten mice/group were inoculated intravaginally with 10<sup>3</sup> pfu/mouse of HSV1-LacZ, HSV1-Ta...
<p>Mice immunized as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.p...
<p>(<b>A-D</b>) 10 weeks old mice were infected intra-vaginally with 6.7×10<sup>4</sup> PFUs HSV-2. ...
<p>Mice were evaluated and scored for individual symptoms. Rough hair (absent = 0, present = 1), act...
<p>Vaccinated and mock-vaccinated mice in challenge groups were challenged thorough the intra-vagina...
<p>BALB/c mice were immunized as described above. One week after the booster immunization, mice were...
<p>(A) Female BALB/c mice were singly-infected with either 10<sup>5</sup> PFU HSV-2 (H5) or with 10<...
<p>Groups of mice (n = 10) were infected by the intravaginal route with a single dose (ranging from ...
<p>The percentage (A) and degree (B) of morbidity of Balb/c mice immunized with pE1D2, pE2D2 and con...
WT and Usp12-/- mice were infected with HSV-1 virus (1 × 107 PFU per mouse). (A) Survival rate of WT...
<p>Mice were treated with 2 mg medoxyprogesterone 7 and 3 days prior to vaginal HSV-2 challenge. On ...
<p>(A) Pre challenge percent change in weight in mock vs vaccinated animals. Percentages normalized ...
<p>Mice were treated with 2 mg medoxyprogesterone 7 and 3 days prior to vaginal HSV-2 challenge. On ...
<p>Mice were immunized twice, three weeks apart, with MVA vectors and challenged three weeks later w...
<p>(<b>A</b>) Design of mouse vaccine-challenge experiment. Mice were immunized in their right, rear...
<p>Ten mice/group were inoculated intravaginally with 10<sup>3</sup> pfu/mouse of HSV1-LacZ, HSV1-Ta...
<p>Mice immunized as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.p...
<p>(<b>A-D</b>) 10 weeks old mice were infected intra-vaginally with 6.7×10<sup>4</sup> PFUs HSV-2. ...
<p>Mice were evaluated and scored for individual symptoms. Rough hair (absent = 0, present = 1), act...
<p>Vaccinated and mock-vaccinated mice in challenge groups were challenged thorough the intra-vagina...
<p>BALB/c mice were immunized as described above. One week after the booster immunization, mice were...
<p>(A) Female BALB/c mice were singly-infected with either 10<sup>5</sup> PFU HSV-2 (H5) or with 10<...
<p>Groups of mice (n = 10) were infected by the intravaginal route with a single dose (ranging from ...
<p>The percentage (A) and degree (B) of morbidity of Balb/c mice immunized with pE1D2, pE2D2 and con...
WT and Usp12-/- mice were infected with HSV-1 virus (1 × 107 PFU per mouse). (A) Survival rate of WT...